Acumen Pharmaceuticals(US:ABOS) Newsfilter·2024-07-28 11:30Core Insights - Acumen Pharmaceuticals announced new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193), a novel therapeutic targeting toxic soluble amyloid beta oligomers (AβOs) for Alzheimer's disease treatment [1][2][3] Group 1: Study Findings - The Phase 1 study highlighted the strength of the study design and the potential of sabirnetug as a best-in-class treatment for early symptomatic Alzheimer's disease [3] - Sabirnetug significantly lowered cerebrospinal fluid (CSF) levels of synaptic biomarkers, indicating its mechanism of action to inhibit synaptic binding of AβOs [4] - An ultra-sensitive assay was developed to detect total levels of sabirnetug in CSF, aiding in accurate quantification of drug exposure in clinical trials [4] Group 2: Patient Experience - Acumen incorporated patient feedback from exit interviews in the INTERCEPT-AD trial to understand their experiences and expectations for treatment [3] - Participants reported symptoms consistent with Alzheimer's disease, with a strong desire for treatments that would slow disease progression and maintain cognitive functions [3] Group 3: Ongoing and Future Trials - The ongoing Phase 2 clinical trial, ALTITUDE-AD, aims to evaluate the efficacy and safety of sabirnetug in patients with early Alzheimer's disease, currently enrolling approximately 540 individuals [5][8] - The study is being conducted at multiple sites in the U.S., Canada, and plans for additional sites in Europe and the UK [5][8] Group 4: Company Overview - Acumen Pharmaceuticals is focused on developing sabirnetug, a humanized monoclonal antibody targeting toxic soluble AβOs, which are believed to be a key factor in Alzheimer's disease pathology [6][9] - The company has received Fast Track designation from the U.S. FDA for sabirnetug in treating early Alzheimer's disease and is advancing its clinical trials following positive Phase 1 results [6][9]